Avapritinib (AVA) is a breakthrough targeted therapy as the first potent inhibitor approved for gastrointestinal stromal tumors (GIST) with PDGFRA D842V mutations. It lacks convenient analytical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results